To independently confirm that the hit compounds inhibit RIN1::ABL binding, and to identify those that effectively block signal transduction in cells, we developed a secondary assay to measure the effect of the compounds in the CML cell line K562. The gene discussed is RIN1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.